26-Aug-2020

CEO, Dr James Garner interviewed on Share Café

Our CEO, Dr James Garner recently conducted video and print interviews with Share Café following the US Food and Drug Administration’s award of Rare Pediatric Disease Designation for paxalisib in Diffuse Intrinsic Pontine Glioma (DIPG) and Fast Track Designation for paxalisib in glioblastoma.

18-Aug-2020

Leading Australian cancer researcher, Dr Matt Dun, interviewed on Channel 7’s Sunrise

Our collaborator, Dr Matt Dun, and Kazia CEO, Dr James Garner, were interviewed on Channel 7’s Sunrise program on the development of paxalisib for Diffuse Intrinsic Pontine Glioma (DIPG) and the grant by the FDA of Rare Pediatric Disease Designation for paxalisib for the treatment of DIPG.

12-Aug-2020

Dr James Garner article in Equity magazine

Our CEO, Dr James Garner recently had an article published in EQUITY magazine – the membership magazine for the Australian Shareholders Association.